Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Thu Apr 16, 7:18AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ovid Therapeutics (OVID), Ascentage Pharma Group International Unsponsored ADR (AAPG) and Johnson & Johnson (JNJ) with bullish sentiments.

Claim 30% Off TipRanks

Ovid Therapeutics (OVID)

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Ovid Therapeutics, with a price target of $5.00. The company’s shares closed last Tuesday at $2.96, close to its 52-week high of $3.45.

According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 1.7% and a 40.4% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Centessa Pharmaceuticals, and Aquestive Therapeutics. ;'>

Ovid Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.00, implying a 79.2% upside from current levels. In a report issued on April 8, TipRanks – PerPlexity also upgraded the stock to Buy with a $3.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Ascentage Pharma Group International Unsponsored ADR (AAPG)

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Ascentage Pharma Group International Unsponsored ADR, with a price target of $48.00. The company’s shares closed last Tuesday at $25.69.

According to TipRanks.com, Amin is a 5-star analyst with an average return of 9.8% and a 46.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, BridgeBio Oncology Therapeutics, and Centessa Pharmaceuticals. ;'>

Currently, the analyst consensus on Ascentage Pharma Group International Unsponsored ADR is a Strong Buy with an average price target of $48.00, an 86.3% upside from current levels. In a report issued on April 13, BTIG also reiterated a Buy rating on the stock with a $48.00 price target.

Johnson & Johnson (JNJ)

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Johnson & Johnson, with a price target of $283.00. The company’s shares closed last Tuesday at $240.10.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.0% and a 54.4% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Arvinas Holding Company, and Vertex Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $262.27 average price target, representing an 11.6% upside. In a report issued on April 2, Erste Group also maintained a Buy rating on the stock.

Read More on OVID:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).